Bedside to Bench and Back
IPOP focuses on translational research and discovery, leveraging the incredible opportunities presented by MSK’s clinical leadership in immuno-oncology and clinical trials. Ultimately, we seek to offer immunogenomic profiling to investigators for patients receiving immunotherapy, through clinical trials or commercial treatments. Beside-to-bench tissue procurement has traditionally been logistically difficult, but can now be seamlessly integrated into highly optimized standard operating procedures. We collaborate with clinical investigators to study tissue (archival, frozen, or fresh) obtained directly from the clinic, operating room, or interventional suite. This material is then processed in the laboratory in a manner optimized for the ultimate immunogenomic deliverables. Data analyses are made available to the team via the cBio for immunogenomics interface, facilitating further collaborations and investigation.
Goals and design:
Which kidney cancer patients respond to immunotherapy?
- exceptional responders
- prospective trials
How do we make kidney cancers that do not respond to current immunotherapies to responsive?
- Test combinations of immune checkpoint blockade agents for kidney cancer to enhance responder rates
- Characterize clinically important neo-antigens
Head and neck squamous cell carcinomas are among the most immune-infiltrated human cancers, and many tumors are poised to respond to immunotherapy, in some cases related to high mutational load in tobacco-associated disease, and in other cases related to human papillomavirus (HPV) infection. Early data show impressive and sometimes durable responses in patients with advanced head and neck cancer. Nevertheless, the majority of patients currently do not experience benefit from immune checkpoint therapy, and much work remains to be done to optimize the number of patients who benefit and the durability of tumor control.
The goals of this project are to conduct correlative research for ongoing clinical trials in head and neck cancer, and to support the translational research infrastructure to facilitate the next steps of clinical investigation.
- Open Trials:
- Upcoming Trials: